Literature DB >> 12517932

Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses.

Frann Bennett1, Deborah Luxenberg, Vincent Ling, I-Ming Wang, Kim Marquette, David Lowe, Nighat Khan, Geertruida Veldman, Kenneth A Jacobs, Viia E Valge-Archer, Mary Collins, Beatriz M Carreno.   

Abstract

The program death 1 (PD-1) receptor and its ligands, PD-1 ligand (PD-L)1 and PD-L2, define a novel regulatory pathway with potential inhibitory effects on T, B, and monocyte responses. In the present study, we show that human CD4(+) T cells express PD-1, PD-L1, and PD-L2 upon activation, and Abs to the receptor can be agonists or antagonists of the pathway. Under optimal conditions of stimulation, ICOS but not CD28 costimulation can be prevented by PD-1 engagement. IL-2 levels induced by costimulation are critical in determining the outcome of the PD-1 engagement. Thus, low to marginal IL-2 levels produced upon ICOS costimulation account for the greater sensitivity of this pathway to PD-1-mediated inhibition. Interestingly, exogenous IL-2, IL-7, and IL-15 but not IL-4 and IL-21 can rescue PD-1 inhibition, suggesting that among these cytokines only those that activate STAT5 can rescue PD-1 inhibition. As STAT5 has been implicated in the maintenance of IL-2Ralpha expression, these results suggest that IL-7 and IL-15 restore proliferation under conditions of PD-1 engagement by enhancing high-affinity IL-2R expression and hence, IL-2 responsiveness.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12517932     DOI: 10.4049/jimmunol.170.2.711

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  112 in total

1.  Immune modulation by a tolerogenic myelin oligodendrocyte glycoprotein (MOG)10-60 containing fusion protein in the marmoset experimental autoimmune encephalomyelitis model.

Authors:  Y S Kap; N van Driel; R Arends; G Rouwendal; M Verolin; E Blezer; N Lycke; B A 't Hart
Journal:  Clin Exp Immunol       Date:  2015-04       Impact factor: 4.330

Review 2.  The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?

Authors:  Craig L Slingluff
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

Review 3.  The balance of immune responses: costimulation verse coinhibition.

Authors:  Sumit K Subudhi; Maria-Luisa Alegre; Yang-Xin Fu
Journal:  J Mol Med (Berl)       Date:  2005-01-04       Impact factor: 4.599

4.  Bystander activation of CD8+ T lymphocytes during experimental mycobacterial infection.

Authors:  Brad Gilbertson; Susie Germano; Pauline Steele; Steven Turner; Barbara Fazekas de St Groth; Christina Cheers
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

5.  Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice.

Authors:  Qing Zhu; Colt Egelston; Susan Gagnon; Yongjun Sui; Igor M Belyakov; Dennis M Klinman; Jay A Berzofsky
Journal:  J Clin Invest       Date:  2010-01-25       Impact factor: 14.808

6.  PD-L1/B7-H1 regulates the survival but not the function of CD8+ T cells in herpes simplex virus type 1 latently infected trigeminal ganglia.

Authors:  Sohyun Jeon; Anthony J St Leger; Thomas L Cherpes; Brian S Sheridan; Robert L Hendricks
Journal:  J Immunol       Date:  2013-05-08       Impact factor: 5.422

7.  Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559).

Authors:  Richard S Hotchkiss; Elizabeth Colston; Sachin Yende; Derek C Angus; Lyle L Moldawer; Elliott D Crouser; Greg S Martin; Craig M Coopersmith; Scott Brakenridge; Florian B Mayr; Pauline K Park; June Ye; Ian M Catlett; Ihab G Girgis; Dennis M Grasela
Journal:  Crit Care Med       Date:  2019-05       Impact factor: 7.598

Review 8.  Tumor infiltrating lymphocytes in ovarian cancer.

Authors:  Phillip P Santoiemma; Daniel J Powell
Journal:  Cancer Biol Ther       Date:  2015-04-20       Impact factor: 4.742

9.  IL-15 temporally reorients IL-10 biased B-1a cells toward IL-12 expression.

Authors:  Amlan Kanti Ghosh; Debolina Sinha; Subhadeep Mukherjee; Ratna Biswas; Tapas Biswas
Journal:  Cell Mol Immunol       Date:  2015-03-09       Impact factor: 11.530

10.  FUT4 is involved in PD-1-related immunosuppression and leads to worse survival in patients with operable lung adenocarcinoma.

Authors:  Chang Liu; Zhi Li; Shuo Wang; Yibo Fan; Simeng Zhang; Xianghong Yang; Kezuo Hou; Jianhua Tong; Xuejun Hu; Xiaonan Shi; Xiaoxun Wang; Yunpeng Liu; Xiaofang Che; Xiujuan Qu
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-24       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.